Latest news and press releases about Serina Therapeutics, Inc. (SER): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy.
Price
| Price | $2.16 |
| Market Cap | $32M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 2.01 |
| EV / EBITDA | -0.95 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -222.42% |
| Return on Invested Capital | -116.37% |
| Return on Assets | -82.03% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALGS · BRNS · CVM · GNTA · GRCE · INMB · JUNS
Explore sector: Healthcare · Biotechnology
More sections of SER: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks